Table 1:
Sociodemographic Characteristics of Newly Diagnosed Carpal Tunnel Syndrome Patients and Bivariate Analyses1 (2010-2017)
| No. (%) | No. (%) | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | Overall Cohort (N=56,593) | Persistent Gabapentinoid Use (N=1,523) | No Persistent Gabapentinoid Use (N=55,070) | P-Value | Persistent Opioid Use (N=5,361) | No Persistent Opioid Use (N=51,232) | P-Value |
| Age | |||||||
| 18-29 | 1,539 (2.7) | 21 (1.4) | 1,518 (2.8) | <0.05 | 171 (3.2) | 1,368 (2.7) | <0.05 |
| 30-39 | 6,165 (10.9) | 122 (8.0) | 6,043 (11.0) | 629 (11.7) | 5,536 (10.8) | ||
| 40-49 | 13,871 (24.5) | 333 (21.9) | 13,538 (24.6) | 1,335 (24.9) | 12,536 (24.5) | ||
| 50-59 | 25,056 (44.3) | 757 (49.7) | 24,299 (44.1) | 2,357 (44.0) | 22,699 (44.3) | ||
| 60-64 | 9,962 (17.6) | 290 (19.0) | 9,672 (17.6) | 869 (16.2) | 9,093 (17.8) | ||
| Female | 37,158 (65.7) | 1,054 (69.2) | 36,104 (65.6) | <0.05 | 3,611 (67.4) | 33,547 (65.5) | <0.05 |
| Median Household Income | |||||||
| <60,000 | 10,867 (19.2) | 332 (21.8) | 10,535 (19.1) | <0.05 | 1,187 (21.8) | 9,680 (22.1) | <0.05 |
| 60,000-69,999 | 18,138 (32.1) | 465 (30.5) | 17,673 (32.1) | 1,648 (30.5) | 16,490 (30.7) | ||
| 70,000-79,999 | 9,191 (16.2) | 208 (13.7) | 8,983 (16.3) | 836 (13.7) | 8,355 (15.6) | ||
| 80,000-89,999 | 3,721 (6.6) | 76 (5.0) | 3,645 (6.6) | 352 (5.0) | 3,369 (6.6) | ||
| ≥90,000 | 14,676 (25.9) | 442 (29.0) | 14,234 (25.9) | 1,338 (29) | 13,338 (25.0) | ||
| Charlson Comorbidity Index, mean (SD) | 0.5 (1.0) | 0.8 (1.4) | 0.5 (1.0) | <0.05 | 0.6 (1.1) | 0.5 (1.0) | <0.05 |
| Diabetes | 7,845 (13.9) | 381 (25.0) | 7,464 (13.6) | <0.05 | 926 (17.3) | 6,919 (13.5) | <0.05 |
| Region | |||||||
| Northeast | 11,179 (19.8) | 241 (15.8) | 10,938 (19.9) | <0.05 | 846 (15.8) | 10,333 (20.2) | <0.05 |
| North Central | 16,067 (28.4) | 418 (27.5) | 15,649 (28.4) | 1,457 (27.2) | 14,610 (28.5) | ||
| South | 21,040 (37.2) | 680 (44.7) | 20,360 (37) | 2,248 (41.9) | 18,792 (36.7) | ||
| West | 7,870 (13.9) | 172 (11.3) | 7,698 (14) | 770 (14.4) | 7,100 (13.9) | ||
| Unknown | 437 (0.8) | 12 (0.8) | 425 (0.8) | 40 (0.8) | 397 (0.8) | ||
| Insurance | |||||||
| PPO | 33,749 (59.6) | 913 (60.0) | 32,836 (59.6) | <0.05 | 3,127 (60) | 30,622 (58.3) | <0.05 |
| Comprehensive | 2,433 (4.3) | 111 (7.3) | 2,322 (4.2) | 290 (7.3) | 2,143 (5.4) | ||
| HMO | 6,424 (11.4) | 163 (10.7) | 6,261 (11.4) | 682 (10.7) | 5,742 (12.7) | ||
| Point of Service | 4,984 (8.8) | 159 (10.4) | 4,825 (8.8) | 473 (10.4) | 4,511 (8.8) | ||
| Other | 6,110 (10.8) | 126 (8.3) | 5,984 (10.9) | 544 (8.3) | 5,566 (10.2) | ||
| Unknown | 2,893 (5.1) | 51 (3.4) | 2,842 (5.2) | 245 (3.4) | 2,648 (4.6) | ||
| Mental Health Disorders | 11,029 (19.5) | 393 (25.8) | 10,636 (19.3) | <0.05 | 1,347 (25.1) | 9,682 (18.9) | <0.05 |
| Adjustment | 1,428 (2.5) | 53 (3.5) | 1,375 (2.5) | 0.16 | 151 (2.8) | 1,277 (2.5) | 0.15 |
| Anxiety | 4,551 (8.0) | 174 (11.4) | 4,377 (8.0) | <0.05 | 564 (10.5) | 3,987 (7.8) | <0.05 |
| Disruptive | 882 (1.6) | 19 (1.3) | 863 (1.6) | 0.32 | 103 (1.9) | 779 (1.5) | <0.05 |
| Mood | 6,218 (11.0) | 232 (15.2) | 5,986 (10.9) | <0.05 | 797 (14.9) | 5,421 (10.6) | <0.05 |
| Suicide of Self-Harm | 62 (0.1) | 3 (0.2) | 59 (0.1) | 0.23 | 12 (0.2) | 50 (0.1) | <0.05 |
| Personality | 80 (0.14) | 7 (0.5) | 73 (0.1) | <0.05 | 13 (0.2) | 67 (0.1) | <0.05 |
| Psychosis | 105 (0.2) | 5 (0.3) | 100 (0.2) | 0.19 | 18 (0.3) | 87 (0.2) | <0.05 |
| Alcohol or Substance Abuse | 667 (1.2) | 33 (2.2) | 634 (1.2) | <0.05 | 106 (2.0) | 561 (1.1) | <0.05 |
| Other | 912 (1.6) | 23 (1.5) | 889 (1.6) | 0.75 | 116 (2.2) | 796 (1.6) | <0.05 |
| Pain Disorders | 35,371 (62.5) | 1,120 (73.5) | 34,251 (62.2) | <0.05 | 3,779 (70.5) | 31,592 (61.7) | <0.05 |
| Arthritis | 27,184 (48.0) | 869 (57.1) | 26,315 (47.8) | <0.05 | 2,869 (53.5) | 24,315 (47.5) | <0.05 |
| Back | 11,577 (20.5) | 470 (30.9) | 11,107 (20.2) | <0.05 | 1,413 (26.4) | 10,164 (19.8) | <0.05 |
| Neck | 7,753 (13.7) | 286 (18.8) | 7,467 (13.6) | <0.05 | 873 (16.3) | 6,880 (13.4) | <0.05 |
| Other | 12,023 (21.2) | 468 (30.7) | 11,555 (21.0) | <0.05 | 1,448 (27.0) | 10,575 (20.6) | <0.05 |
| Preoperative Gabapentinoid Use | 3,474 (6.1) | 835 (54.8) | 2,639 (4.8) | <0.05 | 702 (13.1) | 2,772 (5.4) | <0.05 |
1
Bivariate analyses were performed for the outcomes new persistent gabapentinoid use and new persistent opioid use.